



(19)

(11) Publication number:

0 307 376  
A1

(20)

## EUROPEAN PATENT APPLICATION

(21) Application number: 88850240.8

(51) Int. Cl.4: A 01 N 63/00

(22) Date of filing: 04.07.88

A 61 L 2/18

//(A01N63/00,59:12,59:00)

(30) Priority: 10.07.87 SE 8702831

(71) Applicant: EWOS AKTIEBOLAG  
Box 618(43) Date of publication of application:  
15.03.89 Bulletin 89/11

S-151 27 Södertälje (SE)

(64) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE(72) Inventor: Knutsson, Maud Inger Christine  
Nygard Åshorn  
S-619 00 Trosa (SE)(74) Representative: Inger, Lars Ulf Bosson  
L + U INGER Patentbyra AB Garvaregatan 12  
S-262 63 Ängelholm (SE)

The title of the invention has been amended (Guidelines for Examination in the EPO, A-III, 7.3).

## (54) Microbiocidal composition.

(57) The present invention relates to a composition having microbiocide effect and comprising iodine and the enzyme lactoperoxidase, whereby it comprises lactoperoxidase in an amount of at least 10 mg/l, a peroxide donor in an amount that gives at least 0.5 mM H<sub>2</sub>O<sub>2</sub>, I<sup>-</sup> in a concentration of at least 10 ppm, and a pH adjusting agent in such an amount that pH is 3.25-7.0, when lactoperoxidase is used, and 3.5-6, when horse radish peroxidase is used, preferably 4.5-6.5.

TABELL 1.

Example Composition	L.P. mg/l								
	1	2	3	4	5	6	7	8	9
L.P. mg/l	10	10	10	100	20	20	20	100	100
HP U/l									
600 U/l	100	100	100	100	100	100	100	100	100
Glucose %	0,3	0,3	0,3	0,3	0,3	0,3	0,3	0,3	0,3
NaSCN ppm									
MgO <sub>2</sub> (25%) ppm									
Iodide as NaI ppm	10	100	100	100	100	100	100	100	100
Urea g/l	80	80	20	20	20	20	20	20	20
Carbamide peroxide									
Citric acid g/l	0,02	0,000048							
Mono-Na-citrate g/l									
Tri-Na-citrate g/l									
pH initially	5,5	6							
after 30 min									
24 hrs	5,1								
48 hrs	5								
L.P. determ. U/l									
after 30 min		0,153							
24 hrs		0,024							
48 hrs									
Absorbancy 460 nm									
after 10 min	0,027	0,031							
24 hrs		0,075							
48 hrs		0,078							

TABELL 1.

Example Composition	TABELL 1.								10 100
	10 LP mg/L	10 HP U7L	10 GOD U/L	10 Glucose %	10 NaSCN ppm	10 MgO <sub>2</sub> (25%) ppm	10 Iodide as NaI ppm	10 Urea g/l	
10 LP mg/L	100	100	100	0,3	6	300	100	100	100
HP U7L				0,3	6	300	1000	100	100
GOD U/L				6	6	300	1000	100	100
Glucose %				6	6	300	1000	100	100
NaSCN ppm				6	6	300	1000	100	100
MgO <sub>2</sub> (25%) ppm				300	300	300	300	300	300
Iodide as NaI ppm				100	500	1000	1000	100	100
Urea g/l									
Carbamide peroxide									
Citric acid g/l									
Mono-Na-citrate g/l	2,1	2,1	2,1	2,1	3,9	3,9	3,9	3,9	3,9
Tri-Na-citrate g/l	3,9	3,9	3,9	3,9	5,44	5,44	5,48	5,46	5,43
pH initially	5,9	5,9	5,9	5,9	5,8 (60 min)	5,93	5,93	5,52	5,53
after 30 min						5,93	5,93	5,51	5,53
24 hrs								5,89	5,89
48 hrs									5,89
LP determ. U/L									
after 30 min			0,011		0,3	0,3	0,33	0,37	0,58
24 hrs			0		1,1-0,1	1,1-0,1	0,001	0,002	0,08
48 hrs									0
Absorbancy 460 nm									
after 10 min			0,24		0,877	0,895	0,222	0,25	0,207
24 hrs			0,2		0,699	0,697	0,208	0,239	0,194
48 hrs			0,19						0,203

TABELL 1.

Example Composition	19		Iodophor I	Iodophor II	Iodophor III	Iodophor IV	20	21
	LP mg/l	HP U/l	pH orig	pH 5,5	pH orig	pH 5,5	pH orig	pH 5,5
LP mg/l	1						2.5	2.5
HP U/l	100							
Glucose %	0,1							
NaSCN ppm	6							
MgO <sub>2</sub> (25%) ppm								
Iodide as NaI, ppm	60	60	60	60	60	60	60	60
Urea g/l								
Carbamide peroxide	9,5						94	94
Citric acid g/l	0,05 mM						0,005M	0,055M
Mono-Na-citrate g/l	pH 5,5						pH 5,5	pH 3,5
Tri-Na-citrate g/l							citrato	citrato
pH initially	citrate	buffer					buffer	buffer
5,5	2,74	5,4					5,07	3,64
after 30 min	5,6	2,75	5,5					
24 hrs	5,6	2,95	5,5	3,8				
48 hrs				3,8	5,5			
LP determ. U/l							5,1	3,6
after 30 min								
24 hrs								
48 hrs								
Absorbancy 460 nm								
after 10 min								
24 hrs	0,017	0,444	0,546	0,697	0,820			
48 hrs	0,00	0,404	0,516	0,677	0,791			
	0,04							

TABELL 2.

Example	Bacteria	1	2	3	4	5	6	7.	8	9
E. coli inoc.		$9,7 \times 10^6$	$1,7 \times 10^6$	$1,6 \times 10^7$	$1,6 \times 10^7$	$6,6 \times 10^6$	$6,6 \times 10^6$			
30 sek		$7,0 \times 10^1$	<1	<1	<1	$>10^6$	$>10^6$			
2 min		<1	<1	<1	<1	$>10^6$	$>10^6$			
10 min		<1	<1	<1	<1					
60 min		<1	<1	<1	<1					
120 min										
240 min										
Staph. aureus inoc.		$1,8 \times 10^6$	$2,9 \times 10^6$	$2,4 \times 10^7$	$2,4 \times 10^7$	$1,9 \times 10^7$	$1,9 \times 10^7$	$5,5 \times 10^7$	$3,7 \times 10^7$	$3,7 \times 10^7$
30 sek		$>10^7$	$>10^7$	<1	<1	$>10^7$	$>10^7$			
2 min		$1,8 \times 10^6$	<1	<1	<1	$>10^7$	$>10^7$			
10 min		<1	<1	<1	<1					
60 min		<1	<1	<1	<1	$>10^7$	$>10^7$	$<10$	$<10$	$<10$
120 min										
240 min										
Strep/Staph <sup>1}</sup> inoc.		$2,2 \times 10^6$	$1,5 \times 10^6$			$3,2 \times 10^4$	$7,2 \times 10^6$			
30 sek		<1	10			$5,3 \times 10^6$	$5,3 \times 10^6$	$3,0 \times 10^7$	$2,8 \times 10^7$	$2,8 \times 10^7$
2 min		<1	90			$>10^6$	$>10^6$			
10 min		<1	<1							
60 min		<1	<1			$2 \times 10^2$	$3 \times 10^2$	$<10$	$<10$	$<10$
120 min										
240 min										

1) Strep. agal S-B 8 has been used for Examples 1 and 2. Strep. uberis has been used for Examples 5 and 6. Staph. aureus has been used for Examples 7-9, whereby the solutions were 29 hrs old. The solutions 1-6 were 1 hr old.

TABELL 2.

Example	10	11	12	13	14	15	16	17	18
<i>Bacillus</i>									
E. coli inoc.									
30 sek									
2 min									
10 min									
60 min									
120 min									
240 min									
<i>Staph. aureus</i> inoc.									
30 sek	5,6x10 <sup>7</sup>	6,2x10 <sup>8</sup>	5,6x10 <sup>7</sup>	3,8x10 <sup>7</sup>	3,8x10 <sup>7</sup>	4,9x10 <sup>7</sup>	4,9x10 <sup>7</sup>	4,5x10 <sup>7</sup>	4,5x10 <sup>7</sup>
2 min			<10	4,4x10 <sup>2</sup>	50	2,9x10 <sup>2</sup>	10	6,5x10 <sup>2</sup>	
10 min			<10	<10	40	<10	<10	<10	
60 min			<10	<10	<10	<10	<10	<10	
120 min			<10	<10	<10	<10	<10	<10	
240 min			<10						
S. aureus 2) inoc.	2,0x10 <sup>3</sup>	<10							
30 sek	3,8x10 <sup>7</sup>	7,7x10 <sup>6</sup>	3,8x10 <sup>7</sup>	3,8x10 <sup>7</sup>	3,8x10 <sup>7</sup>	4,9x10 <sup>7</sup>	4,9x10 <sup>7</sup>	3,1x10 <sup>7</sup>	3,1x10 <sup>7</sup>
2 min			1,1x10 <sup>2</sup>	<10	6,0x10 <sup>2</sup>	2,0x10 <sup>3</sup>	<10	20	
10 min			20	<10	<10	100	<10	<10	
60 min			<10	<10	<10	<10	<10	<10	
120 min			<10	<10	<10	<10	<10	<10	
240 min			<10	1,2x10 <sup>3</sup>					

2) The solutions of the compositions used were 29 hrs old, with the exception for the solutions 13-18, which were 5 hrs old

21

TABELL 2.

Example Bacteria	19		Iodophor I Iodophor II Iodophor II		20
	pH orig	pH 5,5	pH orig	pH 5,5	
<i>E. coli</i> inoc.					
30 sek					
2 min					
10 min					
60 min					
120 min					
240 min					
<i>Staph. aureus</i> inoc.					
30 sek	$3,8 \times 10^7$	$3,6 \times 10^7$	$3,6 \times 10^7$	$4,8 \times 10^7$	$3,9 \times 10^7$
2 min	$>10^7$	$590$	$2,0 \times 10^3$	$4,9 \times 10^4$	$1,7 \times 10^7$
10 min	$>10^7$	$<10$	$100$	$30$	$1,1 \times 10^5$
60 min	$>10^7$	$<10$	$<10$	$<10$	$<10$
120 min	$20$	$<10$	$200$	$<10$	$4,0 \times 10^3$
240 min					
<sup>2)</sup> <i>Staph. aureus</i> inoc.					
30 sek	$4,9 \times 10^7$	$2,8 \times 10^7$	$2,8 \times 10^7$	$3,1 \times 10^7$	$3,1 \times 10^7$
2 min	$>10^7$	$3,0 \times 10^3$	$4,0 \times 10^4$	$<10$	$2,7 \times 10^4$
10 min	$>10^7$	$<10$	$500$	$<10$	$170$
60 min	$1,6 \times 10^4$	$<10$	$<10$	$<10$	$600$
120 min	$1,8 \times 10^3$	$<10$	$<10$	$<10$	$600$
240 min					

2) The solutions of the compositions used were 24 hrs old

As evident from Tables 1 and 2 a considerable microbicide effect is obtained by means of the compositions according to the present invention. The remarkable thing is that they functions well at a slightly acidic, almost neutral pH, at which pH iodophores do not function, when pH has been adjusted to substantially neutral value. In the latter case the microbicide effect has almost completely failed.

5 The present composition is present in a water free form, at least concerning the hydrogen peroxide donating/formating part. Thus the composition according to the invention is present preferably in dry form, but can also be present in the form of a paste which comprises two parts which are brought together at the use. Even a liquid composition can be used considering the basic demand, viz that the hydrogen peroxide donating/formating part is kept out of contact with water until in use. Besides a pure dry pulverulent mixture,  
10 15 the composition can be present in the form of tablets and granules as well as double layer tablets which are dissolved in a suitable amount of water prior to use.

The following Examples 22-31 were prepared for comparative testing. Thus compositions according to the present invention were prepared, as well as according to EP-A1-0 175 801. Example 24 is prepared in accordance with Example 5 of EP-A1-0 175 801, and Example 25 is the same as Ex. 24 but for a weaker buffer, 0.01M. Example 27 is the same as Ex. 24 except for the concentration of the buffer and the pH.

15 Table 3 below gives the different compositions of Examples 22-31.

Table 4 below gives the absorbancy at 460 nm for each of the solutions of Ex. 22-31.

Following the UV absorbancy test four compositions were picked out for a bactericide test, viz. the compositions of Ex. 22, 24, 26, and 27, respectively, whereby the compositions were tested against Staph. aureus MJ 13151/84, Staph. aureus 1243/87, Pseudomonas aeruginosa Ps. q. 41, and E. coli A126, respectively, with regard to their bactericide effect. The Staph. aureus strains were inoculated in an amount of  $8 \times 10^7$  cfu/ml, Ps. aeruginosa in an amount of  $1.1 \times 10^8$  cfu/ml, and E. coli in an amount of  $6.8 \times 10^7$  cfu/ml. Surviving cfu were tested for after 30 s, 60 s, 2 min, and 10 min, respectively. The bactericide effect obtained is shown in Table 5 below, whereby the killing effect is given in percentage of inhibition in a log scale. Zero value indicates no or very weak killing capacity, while 100% corresponds to total killing.

Table 3.

Components	22	23	24	25	26	27	28	29	30	31
LP	10	10			10		10	10		
HP			10	10		10			10	10
Phosphate										
buffer	0.1	0.01	0.1	0.01			0.1	0.01	0.1	0.01
Citrate							0.01	0.01		
buffer										
NaI, mM	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
H <sub>2</sub> O <sub>2</sub> , mM	0.1	0.1	0.1	0.1	0.1	0.1				
Urea										
peroxide							0.1	0.1	0.1	0.1
pH	7.0	7.0	7.0	7.0	5.0	5.0	7.0	7.0	7.0	7.0

55

60

65

Table 4.

Example Absorbancy at 460 nm

pH

initially 10 min 30 min 24 hrs initially 30 min

22	0.065	0.063	0.056	0.018	7.0	7.0
23	0.104	0.100	0.091	0.035	7.1	7.1
24	0.000	0.000	0.002	0.000	7.0	7.1
25	0.000	0.000	0.001	0.000	7.1	7.1
26	0.171	0.163	0.160	0.078	5.1	5.1
27	0.183	0.175	0.167	0.070	5.1	5.1
28	0.052	0.048	0.047	0.011	7.0	7.0
29	0.065	0.061	0.059	0.022	7.1	7.1
30	0.003	0.007	0.008	0.003	7.0	7.0
31	0.004	0.007	0.014	0.005	7.0	7.0



EP 88 85 0240

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)						
X	US-A-4 282 324 (S.L. NEIDLEMAN et al.) * Column 2, line 38 - column 3, line 9; column 3, lines 25-32; examples; claims * ---	1-8	A 01 N 63/00 A 61 L 2/18 // (A 01 N 63/00 A 01 N 59:12 A 01 N 59:00 )						
X	CHEMICAL ABSTRACTS, vol. 68, no. 7, 12th February 1968, page 2665, no. 27662h, Columbus, Ohio, US; J.K. SEYMORE: "Iodination of bacteria: a bactericidal mechanism", & J. EXP. MED. 126(6), 1063-78(1967) * Abstract *	1-8							
A	CHEMICAL ABSTRACTS, vol. 99, no. 23, 5th December 1983, page 458, no. 191505v, Columbus, Ohio, US; A.M. SUGAR et al.: "Susceptibility of Blastomyces dermatitidis strains to products of oxidative metabolism", & INFECT. IMMUN. 1983, 41(3), 908-12 * Abstract *	1-8							
A	CHEMICAL ABSTRACTS, vol. 89, no. 11, 11th September 1978, page 86, no. 85242r, 85243s, Columbus, Ohio, US; E.L. THOMAS et al.: "Cofactor role of iodide in peroxidase antimicrobial action against Escherichia coli", & ANTIMICROB. AGENTS CHEMOTHER. 1978, 13(6), 1000-5; "Oxidation of Escherichia coli sulfhydryl components by the peroxidase-hydrogen peroxide-iodide antimicrobial system", & ANTIMICROB. AGENTS CHEMOTHER. 1978, 13(6), 1106-10 * Abstracts *	1-8	A 01 N A 61 L						
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>27-10-1988</td> <td>FLETCHER A.S.</td> </tr> </table> <p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone      Y : particularly relevant if combined with another document of the same category      A : technological background      O : non-written disclosure      P : intermediate document</p> <p>T : theory or principle underlying the invention      E : earlier patent document, but published on, or after the filing date      D : document cited in the application      L : document cited for other reasons      &amp; : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	27-10-1988	FLETCHER A.S.
Place of search	Date of completion of the search	Examiner							
THE HAGUE	27-10-1988	FLETCHER A.S.							



European Patent  
Office

# EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 88 85 0240

## DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
D,A	EP-A-0 175 801 (J. KESSLER et al.) * Claims * -----	1-8	
TECHNICAL FIELDS SEARCHED (Int. Cl.4)			

The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
THE HAGUE	27-10-1988	FLETCHER A.S.

### CATEGORY OF CITED DOCUMENTS

- X : particularly relevant if taken alone
- Y : particularly relevant if combined with another document of the same category
- A : technological background
- O : non-written disclosure
- P : intermediate document

- T : theory or principle underlying the invention
- E : earlier patent document, but published on, or after the filing date
- D : document cited in the application
- L : document cited for other reasons
- & : member of the same patent family, corresponding document